CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 56 enrolled
Drug / intervention
hyoscine butylbromidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02516098
NCT02516098Phase 1Completed

A Single Center, Single-dose, Double-blind, Randomized, Two Period Crossover, Two Stage Design to Determine Bioequivalence of Two Formulations Containing Hyoscine Butylbromide 10mg Sugar Coated Tablets, Under Fasting Conditions

Boehringer Ingelheim·interventional·Posted Aug 5, 2015·Updated Apr 5, 2017

In Brief

A Phase 1 clinical trial evaluating hyoscine butylbromide for Healthy. Completed, enrolled 56 participants across 1 site.

Detailed Summary

Determine bioequivalence of two forumulations with hyoscine butylbromide 10mg sugar coated tablets.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 5, 2015
Enrollment StartOct 1, 2015
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.9 years ago

Interventions

hyoscine butylbromidedrug